PharmacoEconomics

, Volume 1, Issue 1, pp 20–29

Principles of Pharmacoeconomic Analysis of Drug Therapy

  • Deborah A. Freund
  • Robert S. Dittus
Review Article

Summary

Economic analyses have become increasingly important in healthcare in general and with respect to pharmaceuticals in particular. If economic analyses are to play an important and useful role in the allocation of scarce healthcare resources, then such analyses must be performed properly and with care. This article outlines some of the basic principles of pharmacoeconomic analysis. Every analysis should have an explicitly stated perspective, which, unless otherwise justified, should be a societal perspective. Cost minimisation, cost-effectiveness, cost-utility and cost-benefit analyses are a family of techniques used in economic analyses. Cost minimisation analysis is appropriate when alternative therapies have identical outcomes, but differ in costs. Cost-effectiveness analysis is appropriate when alternative therapies differ in clinical effectiveness but can be examined from the same dimension of health outcome. Cost-utility analysis can be used when alternative therapies may be examined using multiple dimensions of health outcome, such as morbidity and mortality. Cost-benefit analysis requires the benefits of therapy to be described in monetary units and is not usually the technique of choice. The technique used in an analysis should be described and explicitly defended according to the problem being examined. For each technique, the method of determining costs is the same; direct, indirect, and intangible costs can be considered. The specific costs to be used depend on the analytical perspective; a societal perspective implies the use of both direct and indirect economic costs. A modelling framework such as a decision tree, influence diagram, Markov chain, or network simulation must be used to structure the analysis explicitly. Regardless of the choice of framework, all modelling assumptions should be described. The mechanism of data collection for model inputs must be detailed and defended. Models must undergo careful verification and validation procedures. Following baseline analysis of the model, further analyses should examine the role of uncertainty in model assumptions and data.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 3(4): 411–458, 1983CrossRefGoogle Scholar
  2. Blades CA, Culyer AJ, Walker A. Health service efficiency: appraising the appraisers — a critical review of economic appraisal in practice. Social Science in Medicine 25(5): 461–472, 1987CrossRefGoogle Scholar
  3. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics, Harvey Whitney Books Company, Ohio, 1991Google Scholar
  4. Clemen RT. Making Hard Decisions, PWS Kent, Boston, 1991Google Scholar
  5. Crane VS. Economic aspects of clinical decision making: applications of clinical decision analysis. American Journal of Hospital Pharmacy 45: 548–553, 1988PubMedGoogle Scholar
  6. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making 6(2): 85–92, 1986PubMedCrossRefGoogle Scholar
  7. Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. American Journal of Hospital Pharmacy 42: 791–802, 1985PubMedGoogle Scholar
  8. Dittus RS, Roberts SD, Wilson JR. Quantifying uncertainty in medical decisions. Journal of the American College of Cardiology 14(3): 23A–28A, 1989PubMedCrossRefGoogle Scholar
  9. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 5(2): 157–177, 1985PubMedCrossRefGoogle Scholar
  10. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term ‘cost-effective’ in medicine. New England Journal of Medicine 314(4): 253–256, 1986PubMedCrossRefGoogle Scholar
  11. Drummond MF. Principles of economic appraisal in health care, Oxford University Press, Oxford, 1980Google Scholar
  12. Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialised countries. World Health Statistical Quarterly 38(4): 383–401, 1985Google Scholar
  13. Drummond MF, Stoddard GL, Labelle R, Cushman R. Health economics: An introduction for clinicians. Annals of Internal Medicine 107(1): 88–92, 1987aPubMedGoogle Scholar
  14. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford Medical Publications, Oxford, New York, Toronto, 1987bGoogle Scholar
  15. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. Journal of the American Medical Association 262(2): 2879–2886, 1989PubMedCrossRefGoogle Scholar
  16. Eisenhut RD, Dittus RS, Roberts SD, Wilson JR. Comparing averaged-out utilities of probability trees having random parameters. Society for Industrial and Applied Mathematics Journal of Scientific and Statistical Computing 12(5): 1140–1161, 1991Google Scholar
  17. Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme, Commonwealth of Australia, Department of Health, Housing, and Community Services, Canberra, Australia, 1990Google Scholar
  18. Feller W. An introduction to probability theory and its applications, John Wiley & Sons, New York, 1968Google Scholar
  19. Froberg DG, Kane RL. Methodology for measuring health-state preferences. III. Population and context effects. Journal of Clinical Epidemiology 42(6): 585–592, 1989PubMedCrossRefGoogle Scholar
  20. Gafni A. The quality of QALYs: do QALYs measure what they at least intend to measure? Health Policy 13(1): 81–85, 1989PubMedCrossRefGoogle Scholar
  21. Gagnon JP, Osterhaus P. Proposed drug-drug cost effectiveness methodology. Drug Intelligence and Clinical Pharmacology 21: 211–216, 1987Google Scholar
  22. Gramlich EM. Benefit-cost analysis of government programs, Prentice Hall, Englewood Cliffs, 1981 Guyatt G, Drummond M, Feeny D, Tugwell P, Stoddart GL, et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine 22(4): 393–408, 1986CrossRefGoogle Scholar
  23. Henry D. Economic analysis as an aid to subsidisation decisions: the development of the Australian guideline for pharmaceuticals. Pharmacoeconomics 1(1): 54–67, 1992PubMedCrossRefGoogle Scholar
  24. Hill WL. Economic evaluation of pharmacologic therapy. Drug Intelligence and Clinical Pharmacology 20: 594–596, 1986Google Scholar
  25. Hillier FS, Lieberman GJ. Introduction to operations research, Holden-Day, San Francisco, 1974Google Scholar
  26. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991PubMedCrossRefGoogle Scholar
  27. Hillman BJ, Kahan JP, Neu R, Hammons GT. Clinical trials to evaluate cost-effectiveness. Investigational Radiology 24(2): 167–171, 1989CrossRefGoogle Scholar
  28. Howard RA, Matheson JE. The principles and applications of decision analysis, Strategic Decisions Group, Menlo Park, 1984Google Scholar
  29. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1(1): 61–80, 1982CrossRefGoogle Scholar
  30. Kats BP, Hui SL. Variance estimation for medical decision analysis. Statistics in Medicine 8(2): 229–241, 1989CrossRefGoogle Scholar
  31. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs, Wiley, New York, 1976Google Scholar
  32. Klein RW, Dittus RS, Roberts SD. Simulation modeling and health care decision-making: an annotated bibliography, Regenstrief Institute for Health Care, Indianapolis, 1991Google Scholar
  33. Law AM, Kelton WD. Simulation modeling and analysis, McGraw-Hill, New York, 1991Google Scholar
  34. Lohr K (Ed.) Advances in health status assessment. Medical Care 27(3): S1–S293, 1989Google Scholar
  35. Mehres A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalent. Medical Decision Making 9(2): 142–149, 1989CrossRefGoogle Scholar
  36. Oster G. Economic aspects of clinical decision making: applications in patient care. American Journal of Hospital Pharmacy 45: 543–547, 1988PubMedGoogle Scholar
  37. Parsen E. Stochastic processes, Holden-Day, New York, 1962Google Scholar
  38. Raiffa H. Decision analysis: introductory lectures on choices under uncertainty. Addison-Wesley, Reading, 1968Google Scholar
  39. Roberts SD, England WL. Survey of the application of simulation to health care. Simulation Series 10 (1), Society for Computer Simulation, La Jolla, 1981Google Scholar
  40. Roberts SD, Klein RW. Simulation of medical decisions: applications of SLN. Simulation 43(5): 234–241, 1984CrossRefGoogle Scholar
  41. Shepard DS, Thompson M. First principles of cost-effectiveness analysis in health. Public Health Reports 94(6): 535–543, 1979PubMedGoogle Scholar
  42. Simpson CA, Souney PF. Calculating costs of drug therapy: a review of a decade of literature (1977–1987). Clinical Therapeutics 10(6): 616–650, 1988PubMedGoogle Scholar
  43. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical decision making, Butterworth Publishers, Boston, London, Durban, Singapore, Sydney, Toronto, Wellington, 1988Google Scholar
  44. Stokey E, Sechauser R. A primer for policy analysis, Norton, New York, 1978Google Scholar
  45. Torrance GW. Toward a utility theory foundation for health status index models. Health Services Research 11(4): 349–69, 1976PubMedGoogle Scholar
  46. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programmes. Health Services Research 7(2): 118–133, 1972PubMedGoogle Scholar
  47. von Neumann J, Morgenstern O. Theory of games and economic behavior, John Wiley, New York, 1953Google Scholar
  48. Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care, Health Administration Press, Ann Arbor, 1982Google Scholar
  49. Weinstein MC. Economic assessment of medical practices and technologies. Medical Decision Making 1(4): 309–330, 1981PubMedCrossRefGoogle Scholar
  50. Weinstein MC, Fineberg HV. Clinical decision analysis, W.B. Saunders Company, Philadelphia, London, Toronto, 1980Google Scholar
  51. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296(13): 716–721, 1977PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Deborah A. Freund
    • 1
  • Robert S. Dittus
    • 1
  1. 1.School of Public and Environmental Affairs, and Division of General Internal MedicineIndiana UniversityIndianapolisUSA
  2. 2.School of Public and Environmental AffairsIndianapolisUSA

Personalised recommendations